Biomechanical aspects of catheter-related thrombophlebitis

Oren Moshe Rotman*, Dalit Shav, Sagi Raz, Uri Zaretsky, Shmuel Einav

Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel
Email: *orenrotm@post.tau.ac.il

Received 30 September 2013; revised 29 October 2013; accepted 12 November 2013

Copyright © 2013 Oren Moshe Rotman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Short peripheral catheters (SPCs) are the most common intravenous devices used in medical practice. Short peripheral catheter thrombophlebitis (SPCT) is the most frequent complication associated with SPCs, causing discomfort and usually leading to removal of the catheter and insertion of a new one at a different site. The aim of this research was to explore whether biomechanical factors, in addition to biochemical factors, also play a role in the formation of thrombophlebitis. Hence, two of the biomechanical aspects of SPCT were investigated: the physical pressure load exerted by the SPC on the endothelial monolayer, and disturbances in the flow patterns due to the SPC. Endothelial activation was studied by subjecting human umbilical vein endothelial cells (HUVEC) to a weight load of SPC pieces and measuring the release profile of von-Willebrand Factor (vWF) over time, using ELISA. vWF release was chosen as the measure for endothelial activation since it was the major component of the Weibel-Palade Bodies (WPBs), which underwent exocytosis by endothelial cells during activation. Flow patterns were analyzed on a 3D computational fluid dynamics (CFD) model of a brachiocephalic vein with SPC. vWF release profiles were significantly higher in the HUVECs subjected to the load, indicating HUVEC activation. CFD simulations demonstrated a decrease in flow velocities along the catheter body, between the catheter and the vein, due to an enlarged boundary layer. Results indicate that the contact region between the SPC body and the vein wall can be partially responsible for SPCT development, and inflammatory and coagulatory processes initiated by stimulated endothelial cells may be amplified due to disturbed blood flow.

Keywords: Endothelial Activation; vWF; Thrombophlebitis; Phlebitis; Short Peripheral Catheters; Infusion; Intravenous Access; CFD

1. INTRODUCTION

Short peripheral catheters (SPC) are the most widely used intravenous devices in medical practice today, particularly in hospitals and intensive care units. The SPC is commonly inserted into veins of the upper extremities to administer fluids, medications and blood products, or for prophylaxis before procedures. Short peripheral catheter thrombophlebitis (SPCT) is the most frequent complication associated with SPCs, with prevalence in hospitalized patients ranging from 2.6% [1] to 77.5% [2]. This inflammatory process of the vein wall is characterized by pain, tenderness, warmth, erythema, swelling, and sometimes palpable thrombosis of the cannulated vein. In the past, SPCT was thought to be initiated by infection from the insertion site, but studies of catheter tip cultures suggest it may be mediated or initiated by a noninfectious inflammatory process [1,3-6]. Moreover, SPCT symptoms such as local swelling and erythema on the skin surface commonly appear along the venous track [7], making the catheter penetration wound not necessarily initiate the inflammatory process. These findings led us to hypothesize that the inflammatory process of SPCT is initiated by the interaction between the catheter body, the vein wall, and the blood flow.

SPCT causes discomfort and usually results in removal of the catheter and insertion of a new one at a different site. Repeated episodes can lead to venous access difficulties and more invasive procedures, such as central venous catheter placement. This usually results in delayed administration of parenteral medications, lengthened hospital stay and increased costs [6]. Several mechanisms of SPCT pathogenesis have been suggested, including vein wall injury combined with stasis and inflammation that lead to thrombosis [8], and sterile inflammation caused by chemical irritation of the endothel-
lium due to the infusate or catheter material [9-11]. Despite the numerous studies, the pathogenesis of SPCT remains unclear.

Endothelial cells, which act as the barrier between blood and organ tissues, have the capability to regulate local inflammation and coagulation reactions. Where the immediate response is needed, such as at sites of vascular injury, the endothelial cells are activated and support local recruitment of leukocytes and platelets. This recruitment is mediated by the release of the contents of Weibel-Palade Bodies (WPBs) [12]. While a variety of chemical stimulations for WPBs exocytosis are reported in the literature, information is sparse on the effect of physical pressure of a foreign body, such as that exerted by SPCs on endothelial cells.

Flow disturbances are known to affect platelet activation and coagulation by accumulation of shear stresses in recirculation regions and jets [13], and in stagnation regions due to insufficient flush of highly potent coagulation substances. Such flow regimens may exist in the vicinity of the SPC and participate in the inflammatory and coagulatory processes. To the best of our knowledge, there are no reports on flow patterns in the context of SPCT.

The present study is a pioneering work that evaluates the possible effect of two biomechanical aspects of SPCT development: 1) physical pressure of the SPC on the vein wall that irritates and activates the endothelial cells, and 2) flow disturbances in the vicinity of the catheter.

2. MATERIALS AND METHODS

The effect of physical pressure load of SPCs on vein walls was studied in vitro in cultured endothelial cells. Flow patterns in a cannulated vein model were examined using computational flow dynamics (CFD) simulations.

2.1. In Vitro Experiments

Fluorinated ethylene propylene (FEP) 16 gauge (1.3 mm inner diameter, 1.7 mm outer diameter) short peripheral infusion catheters (Ven-O-Lit®) were placed over human umbilical vein endothelial cells (HUVEC). Chemical reactions of the cells to the catheter material were avoided by employing only genuine infusion catheter material. The catheters were cut into 1 cm long pieces, into which 0.7 cm long stainless steel pins were inserted to prevent the catheter pieces from floating in the medium (Figure 1), forming weights of approximately 75 mg each. This weight was chosen after banding similar SPCT units on digital scales for up to 30°, an angle that represents the entrance orientation of the SPC into the vein. Each of these weights exerted a physical pressure load of approximately 67 Pa (0.5 mmHg), estimated by dividing the weight by the contact surface area. Fourteen weights were then placed over a monolayer of HUVEC in each well of a 12-well plate, in a static flow environment, with a confluency of more than 95%. The HUVEC samples were divided into two groups of 3 samples each: the test group, which was subjected to the weight load, and a control group. The two groups were sampled simultaneously. For statistical purposes, the in vitro protocol was repeated twice in a non-dependent fashion, each time using a different cell passage. HUVEC activation was measured by quantification of von-Willebrand Factor (vWF) release, which is the major component of the WPBs and responsible for platelet adhesion to stimulated endothelial cells [12]. Increased vWF release over time compared with the control group will indicate WPB exocytosis—evidence of the increased HUVEC activation that promotes both inflammatory and coagulatory responses. vWF release was chosen over other components of the WPBs because it is abundant and therefore easy to detect.

2.1.1. Cell Culture

HUVEC (Lonza) were grown in MCBD-131 medium supplemented with 5% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Biological Industries Beit Haemek, Israel), 2 ng/ml insulin, 0.5 ng/ml epithelial growth factor (Sigma Aldrich), 2 ng/ml basic-fibroblasts growth factor (bFGF) (PeproTech, Inc., USA) and 1 μg/ml hydrocortisone (Sigma Aldrich) cultured at 37°C, 5% CO₂, in a humidifier incubator. Cells from passages 5 - 10 were used. Cell morphology and confluence were inspected with a Nikon eclipse TS100 phase inverted microscope and captured with a Nikon Coolpix 4500 digital camera.

2.1.2. vWF Measurement

Cells were seeded at near confluence density of 20,000 cells/cm² on a 0.1% gelatin (Sigma Aldrich) coated 12-well plate. When the cells reached 100% confluence, the medium was replaced and the weights were placed on the cells. Medium samples were collected and kept at −20°C until analyzed. During incubation the cells were kept in a
humidifier incubator at 37°C and 5% CO₂. Samples were taken from the wells of both groups at four different times: at the beginning of the experiment (t = 0), and after 20, 40 and 60 minutes. Sixty minutes was found to be sufficient for this setup after several trials with different time scales, as elaborated in the Discussion section. Quantification of vWF was done using Assay-Max ELISA kit (AssayPro). Briefly, samples were incubated for 2 hours using a 96-well microplate coated with murine monoclonal antibody against vWF, after which the samples were removed and the wells were incubated for 60 minutes with biotinylated vWF antibody for another 30 minutes with streptavidin-peroxidase conjugate. The plate was then incubated for 10 minutes with a stabilized peroxidase chromogen substrate, after which a stop solution (containing 0.5 N hydrochloric acid) was added to the chromogen solution. The plate was read at 450 nm by a spectrophotometer (SpectraMax 340PC384, Molecular Devices Corp., Sunnyvale CA, USA). All incubations were performed at 37°C. The wells were washed 5 times between each step using the wash buffer supplied in the kit. For each procedure, a calibration curve was calculated using a human vWF standard protein provided in the kit.

2.1.3. Statistical Analysis
Statistical analysis was performed by ANOVA with repeated measures (over time) with covariance structure of compound symmetry, using SPSS software (SPSS Inc.), and using the vWF concentration results as input. Significance level was considered as p < 0.05.

2.2. Numerical Simulations

2.2.1. Governing Equations
The equations governing continuity (Eq.1) and momentum (Eq.2) for incompressible, viscous and laminar blood flow were:

\[ \nabla \cdot \mathbf{U} = 0 \]  
\[ (U \cdot \nabla)U = -\frac{1}{\rho} \nabla P + \mu \nabla^2 U \]

where \( U \) is the velocity vector, \( P \) is the static pressure, \( \rho \) is the fluid density, and \( \nu \) is the kinematic viscosity.

2.2.2. Boundary Conditions
Cephalic vein flow rate is normally 28 ml/min for a vein diameter of 2.3 mm [14]. In order to keep the Reynolds number (Re) in our enlarged model of 5 mm diameter similar to its physiological value, the flow rate was adjusted to 60 ml/min (Re = 73). The effect of flow of three additional flow rates was examined: 28 ml/min (Re = 34), 45 ml/min (Re = 55), and 75 ml/min (Re = 91). The flow rates were applied to the vein by setting a constant average velocity at the vein inlet (2.38 cm/s, 3.87 cm/s, 5.1 cm/s, and 6.38 cm/s for flow of 28 ml/min, 45 ml/min, 60 ml/min, and 75 ml/min, respectively). Volume outflow condition was set at the vein outlet, meaning that all the volume of flow in the model was drained through the outlet surface. Symmetry condition was applied to the model symmetry plane, such that the velocity gradients across this plane were equal to zero. No slip condition was defined at any of the interfaces between the blood and the catheter or vein walls. The fluid properties were set as whole blood, with density of \( \rho = 1060 \text{ Kg/m}^3 \), and dynamic viscosity of \( \mu = 3.5 \text{ mPa}\cdot\text{s} \).

2.2.2.5. Geometry and Computational Meshing
The computational model geometry was that of a 3D cannulated cephalic vein (Figure 2). The 3D geometry and the meshing were designed using GAMBIT (Fluent Inc.). While the cephalic vein diameter usually ranges from 1.9 - 3.9 mm, reaching from 1 mm to over 6 mm in actual measurements [14,18,19], we chose a 5 mm inner diameter and 85 mm long straight tube section to make it compatible with the in vitro model in our laboratory. A 16 gauge (1.3 mm inner diameter, 1.7 mm outer diameter) catheter was placed inside the vein with an entrance orientation of 30° relative to the vein symmetry axis. The catheter length from its contact with the vein was defined as 25 mm, and was set to be sunk 0.25 mm into the vein wall and underlying tissue to simplify the meshing in the contact area. The vein length upstream to the catheter insertion site was extended by 23 mm to allow the flow to develop before it reached the catheter. The catheter lumen length was set for 10 mm from the catheter tip backwards. The model was cut along its plane of symmetry.
Figure 2. The computational model geometry: (A) side view of the entire geometry, (B) side view zooming in on the catheter inside the vein, (C) further zooming in on the catheter lumen and tip, and (D) diagonal view of the model. Legend: (1) catheter entrance, (2) catheter lumen, (3) catheter tip, (4) vein lumen, (5) vein entrance, and (6) catheter insertion site.

(plane YZ) to save computational time.

The 3D geometry was converted with GAMBIT (Fluent Inc.) into discrete mesh using 1,010,690 hexahedral and tetrahedral elements. Maximum element size was \(8.75 \times 10^{-3}\) mm\(^3\), and the total volume of the computational model was 805.29 mm\(^3\).

Mesh convergence study was performed to ensure that the solution in each case differed by no more than 1% in the velocity values.

3. RESULTS

3.1. vWF Concentrations

The data are summarized in Figure 3. In experiment repetition number 2, the concentrations of samples Control 1 - 3 and Test 2 - 3 at \(t = 0\) were manually set to 0 mU/ml, since the values achieved by the calibration curve were negative and close to zero. The data of Control 3 and Test 3 for \(t = 40\) minutes in experiment repetition 2 were discarded from the statistical analysis due to inappropriate manipulation of the relevant samples. The elevation in vWF concentration in the medium over time was considerably higher for most samples of the test group compared with the corresponding samples of the control group. The overall time course was significant (\(p < 0.001\)) in both the control and test groups. The interaction between time course and experimental repetition was not significant (\(p = 0.986\)). Most importantly, the interaction between time course and groups was significant (\(p = 0.013\)), evidenced by the increased release of vWF in the test group. The averages of the time steps also differed significantly between the control and test groups (\(p = 0.03\)).

3.2. Cell Morphology

Cells in the control group (Figure 4) showed no differences between \(t = 0\) and \(t = 60\) in cell alignment and confluence density: at both time points cell confluence remained almost 100% with no signs of cell mitosis or stress, and the cells remained stretched with no preferred orientation in the field of view. In contrast, the test group cells exhibited significant changes between \(t = 0\) and \(t = 60\): their number had decreased, resulting in cell-free areas throughout the field of view; some of the remaining ones had assumed a round shape, suggesting they were about to detach, and several had become less smooth, denoting stress. In addition, the medium contained a substantial amount of debris (not seen in the images).

Figure 3. Graphic representation of vWF concentrations in the medium, measured by ELISA. The concentrations are presented as mean ± standard deviation.

Figure 4. Images of HUVEC taken at time points \(t = 0\) minutes ((A) and (C)) and \(t = 60\) minutes ((B) and (D)). The white dashed lines mark areas clear of cells. The white arrows point to round shaped cells.
3.3. CFD Simulation

The fluid path-lines smoothly followed the catheter outer surface at the insertion site, in the region where the catheter met the opposite wall of the vein, and along the catheter body. The catheter insertion site was free of flow disturbances and there was no apparent effect on the flow patterns downstream along the catheter wall. Two untoward phenomena were noticed: 1) As the flow passed the catheter tip (Figure 5), a small recirculation region appeared partially inside the catheter lumen. The recirculation region was 1.7 mm long in the 60 ml/min flow rate case, with no significant difference at the other examined rates (range 1.64 mm to 1.82 mm). The surface area in which there were WSS below 0.1 Pa grew larger as the flow decreased. Goel and Diamond [18] showed that the maximum WSS at which red blood cells adhere to platelets, neutrophils, and polymerized fibrin—adhesion that supports increased thrombus formation—is 0.1 Pa. The WSSs in the vein model without the catheter were 0.135 Pa, 0.23 Pa, 0.30 Pa, and 0.38 Pa for flow rates of 28 ml/min, 45 ml/min, 60 ml/min, and 75 ml/min, respectively. (2) The second phenomenon was a significant decrease in the flow velocity and WSS (Figure 6) on both sides of the catheter (along the x axis) as a result of an enlarged boundary layer. The mean axial velocities of the profiles with the catheter (Figure 7) were reduced on average by a factor of 2.76 due to the catheter. In contrast, maximal axial velocities (along the y axis) increased in the center of the vein lumen due to the catheter: increases of 0.81 cm/s, 1.18 cm/s, 1.39 cm/s, and 1.53 cm/s for the flow rates of 28 ml/min to 75 ml/min. This, however, did not significantly affect the vein maximal WSS on the y-axis (0.2 Pa, 0.31 Pa, 0.41 Pa, and 0.51 Pa for flow rates of 28 ml/min, 45 ml/min, 60 ml/min, and 75 ml/min, respectively).

4. DISCUSSION

The elevated concentrations of vWF in the test group indicate that the HUVEC was stimulated by the catheter weights. The slight rise in vWF over time in the control group can be accounted for by the known normal secretion of small amounts of vWF by endothelial cells [19]. This is supported by the absence of change in cell shape and confluence in this group (Figure 4). The large difference in vWF concentration between experiment repetitions 1 and 2 can be attributed to the fact that each of the repetitions was performed independently on cells from a different passage [20]. Despite the wide variation, the vWF release profile of the test group differed significantly over time from that of the control group in both independent repetitions. The higher release profiles reflected in the mean concentrations suggest ongoing stimulus of the test group cells.

Unlike sustained hydrostatic pressure, the catheter is a physical impediment to metabolite transport processes between the culture layer and the nutrient medium. While sustained hydrostatic pressure of up to 7 mmHg stimulates HUVEC proliferation [21], a relatively low physical pressure of less than 1 mmHg in our study caused cell activation and death. The bald areas clearly seen in Figure 4(D) are those of the greatest physical load and most probably the contact areas between the cells and the catheter pieces. Moreover, in areas where the cells remained dense, some of them changed shape from elongated and stretched to rounded, indicating a disturbance or stress.

The mean axial velocities in proximity to the vein wall (on the x-axis), obtained by CFD analysis, were reduced on average by a factor of 2.76 when the catheter was placed. The WSSs in this region were also reduced, creating a surface area surrounding the catheter of WSSs below 0.1 Pa (Figure 6). This reduction was caused by...
Figure 7. (A) Front view of the axial velocity contours at 60 ml/min vein flow: Top—vein with a catheter. Bottom—vein without a catheter. The horizontal white lines with rectangles (vein with a catheter) and triangles (vein without a catheter) are the lines along which velocity profiles were sampled for comparison. (B) Axial velocity profiles for the different vein flow rates examined, with and without a catheter, focusing on the region between the catheter and the vein wall on the x-axis (marked in A by a red rectangle).

an enlarged boundary layer between the vein wall and the catheter body. It was expected that the lower WSSs themselves would not activate the endothelial cells, as the WSSs in veins were naturally very low. Nor did the presence of the catheter have a marked effect on the WSSs. We believe that the major effect of the reduced velocities and WSS was to create a supportive environment for adhesion of rolling leukocytes and platelets to activated endothelium, and to each other, promoting a local inflammatory process in the vein wall and thrombosisis formation in the lumen [12]. This mechanism is supported by Goel and Diamond’s work [18] showing that a WSS below 0.1 Pa enables the circulating red blood cells to adhere to platelets, neutrophils, and polymerized fibrin, resulting in thrombus growth. The *in vitro* results confirmed our hypothesis that the endothelial cells would be activated in the precise location of contact between the catheter and the vein wall, the same location where we observed that significantly reduced flow velocities and reduced WSSs. While our hypothesis appears to have been proven, it needs confirmation from studies of endothelial activation under direct flow conditions.

Another important flow disturbance was the recirculation region that appeared at the catheter tip, partially inside the catheter lumen. A recirculation region in such a location can amplify local inflammatory and coagulatory processes, and slowly dilute the catheter lumen with blood products that may clot and eventually block the lumen and render it non-functional.

According to the CFD results, the flow rate did not seem to have a significant effect on the flow field, as the flow patterns for all simulated rates smoothly followed the catheter outer surface from insertion site to catheter tip. Nor did the size of the recirculation region at the catheter tip appear to be affected by the flow rate. The reduced flow rate did, however, slightly increase the region of very low WSSs around the catheter. It might be that low flow rates create a larger surface area with the potential to promote the rapid thrombus formation.

The findings of this research support the hypothesis that biomechanical factors participate in SPCT pathogenesis, and explain the mechanisms of the common complication associated with peripheral catheters. Most of the improvements in SPCs in recent years consisted of changes in the polymeric material of the cannula. Our results point to the need for geometric modifications to the SPC that will eliminate the contact between the catheter body and the vein wall and avoid the formation of flow stagnation and recirculation regions. Two such geometric modifications are illustrated in Figure 8: significant shortening of the SPC to avoid contact between the cannula and the opposite vein wall, and a protrusion on the cannula outer surface as an anchor to prevent the cannula from slipping outside the vein.

The biomechanical mechanism suggested by the results of the numerical simulations and *in-vitro* experiments conducted in this study involves prolonged irritation and activation of the endothelial cells by the SPC due to physical contact between them, and flow disturbances caused by the catheter that promoted local inflammatory and coagulatory processes. These flow patterns most likely support, rather than initiate, local reactions.

As a pioneering work, this study has limitations that
will need to be addressed in future research. The most serious one is that the in vitro experiments and the numerical simulations were conducted separately. Because incorporating a flow system into the HUVEC experimental setup would have diluted the vWF concentrations to an undetectable level, we chose at this stage to investigate the flow and the catheter-HUVEC interaction separately. We are planning a second generation system that will link the simulations to the experiments in a more robust manner. Another limitation is the difference between the time scale simulated in vitro with the HUVEC and the time scale for SPCT in vivo. The 60-minute period chosen for the in vitro experiment was found to be sufficient after several trials with different scales. While in clinical practice the time scale for SPCT is approximately 3 days [22], our choice of 60 minutes is justified on a number of fronts. As mentioned above, bald areas free of cells remained in the culture at 60 minutes, after which the cell numbers were no longer comparable and there was no reason to continue the experiment. The time scale is affected by factors other than the tested biomechanical ones: for example, the in vitro test had no flow, which meant that active substances secreted by the cells over time did not flush away. The absence of this flow, which meant that active substances secreted by the mechanical ones: for example, the calcium ionophore A23187 and by phorbol ester PMA, the HUVEC had secreted about 40% of their total vWF. Another limitation of the study was that irritation of the vein wall by the catheter tip and possible mechanical injury during the catheter insertion were not investigated. Such injuries to the vein wall could expedite local inflammatory and coagulatory reactions. We chose to focus on more “chronic” biomechanical factors that take place while the SPC is in-situ, and not on factors that can be avoided by better manipulation by the medical staff.

Despite of the limitations, this is the first study to investigate biomechanical aspects of SPCT. The results support our hypothesis and lay the groundwork for more comprehensive investigations that will examine the effect of different pressure loads on HUVEC activation, the incorporation of flow in the in vitro experiments, and the simulation of the bending of the SPC on the vein wall. Such studies will enhance our understanding of the effects of load on endothelial cells.

5. ACKNOWLEDGEMENTS

The study was partially supported by the Drown Foundation and the Berman Fund.

REFERENCES


http://dx.doi.org/10.1093/jac/dkh056


http://dx.doi.org/10.1093/bja/57.2.220


http://dx.doi.org/10.1182/blood-2008-01-078204


http://dx.doi.org/10.1080/0953710031000092839


http://dx.doi.org/10.1115/1.3168362


http://dx.doi.org/10.1016/S1350-4533(00)00046-1


http://dx.doi.org/10.1172/JCI101499


http://dx.doi.org/10.1182/blood-2002-03-0712


http://dx.doi.org/10.1182/blood-2003-02-0599


http://dx.doi.org/10.1016/j.biomaterials.2005.02.024


http://dx.doi.org/10.1161/01.RES.84.3.315


http://dx.doi.org/10.1016/j.ajic.2011.01.003


http://dx.doi.org/10.1073/pnas.0602035104